

Citations and Reference Literature: Methionine

Citations

1. Toborek M, Hennig B. Is methionine an atherogenic amino acid? *J Opt Nutr* 1994;3:80-83.
2. Troen AM, Lutgens E, Smith DE et al. The atherogenic effect of excess methionine intake. *Proc Natl Acad Sci U S A* 2003;100:15089-15094.
3. Muller T, Woitalla D, Hauptmann B et al. Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease. *Neurosci Lett* 2001;308:54-56.
4. Skoglund LA, Skjelbred P. Comparison of a traditional paracetamol medication and a new paracetamol/paracetamol-methionine ester combination. *Eur J Clin Pharmacol* 1984;26:573-577.
5. Neuvonen PJ, Tokola O, Toivonen ML, Simell O. Methionine in paracetamol tablets, a tool to reduce paracetamol toxicity. *Int J Clin Pharmacol Ther Toxicol* 1985;23:497-500.
6. Neuvonen PJ, Simell O, Tokola O. Why not add methionine to paracetamol tablets? *Br Med J Clin Res Ed* 1986;293:958.
7. McAuley DF, Hanratty CG, McGurk C et al. Effect of methionine supplementation on endothelial function, plasma homocysteine, and lipid peroxidation. *J Toxicol Clin Toxicol* 1999;37:435-440.
8. Robertson DR, Higginson I, Macklin BS et al. The influence of protein containing meals on the pharmacokinetics of levodopa in healthy volunteers. *Br J Clin Pharmacol* 1991;31:413-417.
9. Meininger V, Flamier A, Phan T et al. [L-Methionine treatment of Parkinson's disease: preliminary results]. *Rev Neurol (Paris)* 1982;138:297-303.
10. Smythies JR, Halsey JH. Treatment of Parkinson's disease with L-methionine. *South Med J* 1984;77:1577.
11. Pearce LA, Waterbury, L.D. L-Methionine: a possible levodopa antagonist. *Neurology (Minneapolis)* 1974;24:640.
12. Surtees R, Hyland K. L-3,4-Dihydroxyphenylalanine (levodopa) lowers central nervous system S-adenosylmethionine concentrations in humans. *J Neurol Neurosurg Psychiatry* 1990;53:569-572.
13. Kuhn W, Roebroek R, Blom H et al. Elevated plasma levels of homocysteine in Parkinson's disease. *Eur Neurol* 1998;40:225-227.
14. Muller T, Werne B, Fowler B, Kuhn W. Nigral endothelial dysfunction, homocysteine, and Parkinson's disease. *Lancet* 1999;354:126-127.
15. Muller T, Woitalla D, Fowler B, Kuhn W. 3-OMD and homocysteine plasma levels in parkinsonian patients. *J Neural Transm* 2002;109:175-179.
16. Muller T, Renger K, Kuhn W. Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration. *Arch Neurol* 2004;61:657-660.
17. Vidarabine (Vira-A). *Med Lett Drugs Ther* 1977;19:42-43.
18. Cantoni GL, Aksamit RR, Kim IK. Methionine biosynthesis and vidarabine therapy. *N Engl J Med* 1982;307:1079.
19. Fabianowska-Majewska K, Duley JA, Simmonds HA. Effects of novel anti-viral adenosine analogues on the activity of S-adenosylhomocysteine hydrolase from human liver. *Biochem Pharmacol* 1994;48:897-903.
20. Uden S, Bilton D, Nathan L et al. Antioxidant therapy for recurrent pancreatitis: placebo-controlled trial. *Aliment Pharmacol Ther* 1990;4:357-371.
21. Carmel R, Melnyk S, James SJ. Cobalamin deficiency with and without neurologic abnormalities: differences in homocysteine and methionine metabolism. *Blood* 2003;101:3302-3308.

Reference Literature

- [No authors listed.] Vidarabine (Vira-A). *Med Lett Drugs Ther* 1977;19(10):42-43.
- Apeland T, Mansoor MA, Strandjord RE, et al. Folate, homocysteine and methionine loading in patients on carbamazepine. *Acta Neurol Scand* 2001;103(5):294-299.
- Ben-Shlomo Y, Marmot MG. Survival and cause of death in a cohort of patients with parkinsonism: possible clues to etiology. *J Neurol Neurosurg Psychiatry* 1995;58:293-299.
- Benson R, Crowell B, Hill B, et al. The effects of L-dopa on the activity of methionine adenosyltransferase: relevance to L-dopa therapy and tolerance. *Neurochem Res* 1993;18(3):325-330.
- Bidard JN, et al. Effect de la SAM sur le catabolisme de la dopamine. *J Pharmacol (Paris)* 1977; 8(I):83-93.
- Bidard JN, Fonlupt P, Cronenberger L, et al. [Effect of S-adenosyl-L-methionine on the cerebral and peripheral metabolism of L-dopa.] *Arch Int Physiol Biochim* 1978;86(4):715-724. [French]
- Bidard JN, Sokoloff P, Cronenberger L, et al. [Effect of S-adenosyl-L-homocysteine of dopamine catabolism.] *Arch Int Physiol Biochim* 1979;87(2):253-264. [French]

Citations and Reference Literature: Methionine

- Bidard JN, Fonlupt P, Cronenberger L, et al. [Effect of S-adenosyl-L-methionine on the cerebral and peripheral metabolism of L-dopa.] Arch Int Physiol Biochim 1978;86(4):715-724. [French]
- Burger R, Nowak H. A new medical approach to the treatment of osteoarthritis: report of an open phase IV study with ademetionin (Gumbaral) SAM. Am J Med 1987;83(Suppl 5A):84-88.
- Carretero MV, Latasa MU, Garcia-Trevijano ER, et al. Inhibition of liver methionine adenosyltransferase gene expression by 3-methylcolanthrene: protective effect of S-adenosylmethionine. Biochem Pharmacol 2001;61(9):1119-1128.
- Caruso I, Pietrogrande V. Double blind, multicenter study comparing SAM, naproxen, and placebo in the treatment of degenerative joint disease. Am J Med 1987;83(Suppl 5A):66-71. [Italian]
- Chambers JC, McGregor A, Jean-Marie J, et al. Acute hyperhomocysteinaemia and endothelial dysfunction. Lancet 1998;351:36-37.
- Charlton CG, Crowell B Jr. Parkinson's disease-like effects of S-adenosyl-L-methionine: effects of L-dopa. Pharmacol Biochem Behav 1992;43:423-431.
- Charlton CG, Mack J. Substantia nigra degeneration and tyrosine hydroxylase depletion caused by excess S-adenosylmethionine in the rat brain: support for an excess methylation hypothesis for parkinsonism. Mol Neurobiol 1994;9(1-3):149-161.
- Cheng H, Gomes-Trolin C, Aquilonius SM, et al. Levels of L-methionine S-adenosyltransferase activity in erythrocytes and concentrations of S-adenosylmethionine and S-adenosylhomocysteine in whole blood of patients with Parkinson's disease. Exp Neurol 1997;145(2 Pt 1):580-585.
- Chiang EP, Bagley PJ, Selhub J, et al. Abnormal vitamin B(6) status is associated with severity of symptoms in patients with rheumatoid arthritis. Am J Med 2003;114(4):283-287.
- Coppen A, Metcalfe M, Carroll JD, et al. Levodopa and L-tryptophan therapy in Parkinsonism. Lancet 1972;1:654-658.
- Cowell BG Jr, Benson R, Shockley D, et al. S-adenosyl-L-methionine decreases motor activity in the rat: similarity to Parkinson's disease-like symptoms. Behav Neural Biol 1993;59:186-193.
- Di Rocco A, Rogers JD, Brown R, et al. S-Adenosyl-Methionine improves depression in patients with Parkinson's disease in an open-label clinical trial. Mov Disord 2000;15(6):1225-1229.
- Donaldson WE, Leming TK. Effect of dietary methionine and lysine on the toxicity of ingested lead acetate in the chick. J Nutr 1984;114:2155-2159.
- Dorfman D, DiRocco A, Simpson D, et al. Oral methionine may improve neuropsychological function in patients with AIDS myelopathy: results of an open-label trial. AIDS 1997;11(8):1066-1067.
- Funfstuck R, Straube E, Schildbach O, et al. [Prevention of reinfection by L-methionine in patients with recurrent urinary tract infection.] Med Klin (Munich) 1997;92(10):574-581. [German]
- Garlick PJ. Toxicity of methionine in humans. J Nutr 2006;136(6 Suppl):1722S-1725S. (Review)
- Glorioso S, Todesco S, Mazzi A, et al. Double-blind multicentre study of the activity of S-adenosylmethionine in hip and knee osteoarthritis. Int J Clin Pharmacol Res 1985;5(1):39-49.
- Gomes Trolin C, Regland B, Oreland L. Decreased methionine adenosyltransferase activity in erythrocytes of patients with dementia disorders. Eur Neuropsychopharmacol 1995;5(2):107-114.
- Growdon JH, Melamed E, Logue M, et al. Effects of oral L-tyrosine administration on CSF tyrosine and homovanillic acid levels in patients with Parkinson's disease. Life Sci 1982;30:827-832.
- Heller B, Fischer E, Martin R. Therapeutic action of D-phenylalanine in Parkinson's disease. Arzneim Forsch 1976;26:577-579.
- Holven KB, Aukrust P, Holm T, et al. Folic acid treatment reduces chemokine release from peripheral blood mononuclear cells in hyperhomocysteinemic subjects. Arterioscler Thromb Vasc Biol 2002;22(4):699-703.
- Jacques PF, Bostom AG, Selhub J, et al. Effects of polymorphisms of methionine synthase and methionine synthase reductase on total plasma homocysteine in the NHLBI Family Heart Study. Atherosclerosis 2003;166(1):49-55.
- Kagan BL, Sultzer DL, Rosenlicht N, et al. Oral S-adenosylmethionine in depression: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 1990;147(5):591-595.
- Keating JN, Trimble KC, Mulcahy F, et al. Evidence of brain methyltransferase inhibition and early brain involvement in HIV-positive patients. Lancet 1991;337(8747):935-939.
- Kramer BC, Yabut JA, Cheong J, et al. Toxicity of glutathione depletion in mesencephalic cultures: a role for arachidonic acid and its lipoxygenase metabolites. Eur J Neurosci 2004;19(2):280-286.
- Lamango NS, Ayuk-Takem LT, Nesby R, et al. Inhibition mechanism of S-adenosylmethionine-induced movement deficits by prenylcysteine analogs. Pharmacol Biochem Behav 2003;76(3-4):433-442.
- Leach FN, Braganza JM. Methionine is important in treatment of chronic pancreatitis. Br Med J 1998;316:474. (Letter)
- Lehmann J. Tryptophan malabsorption in levodopa-treated parkinsonian patients. Acta Med Scand 1973;194:181-189.
- Lehmann J. Levodopa and depression in Parkinsonism. Lancet 1971;1:140.

Citations and Reference Literature: Methionine

- Lieber CS, Packer L. S-Adenosylmethionine: molecular, biological, and clinical aspects: an introduction. *Am J Clin Nutr* 2002;76(5):1148S-1150S. (Review)
- Ma J, Stampfer MJ, Giovannucci E, et al. Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. *Cancer Res* 1997;57(6):1098-1102.
- Maree KA, van der Westhuyzen J, Metz J. Interrelationship between serum concentrations of methionine, vitamin B12 and folate. *Int J Vitam Nutr Res* 1990;60(2):136-141.
- Marz R. Medical nutrition from Marz. 2nd ed. Portland, OR: Omni Press; 1997.
- Matthias D, Becker CH, Riezler R, et al. Homocysteine induced arteriosclerosis-like alterations of the aorta in normotensive and hypertensive rats following application of high doses of methionine. *Atherosclerosis* 1996;122(2):201-216.
- McAuley DF, Hanratty CG, McGurk C, et al. Effect of methionine supplementation on endothelial function, plasma homocysteine, and lipid peroxidation. *J Toxicol Clin Toxicol* 1999;37(4):435-440.
- Meininger V, Flamier A, Phan T, et al. [L-Methionine treatment of Parkinson's disease: preliminary results.] *Rev Neurol (Paris)* 1982;138(4):297-303. [French]
- Mirza B, Hadberg H, Thomsen P, et al. The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease. *Neuroscience* 2000;95:425-432.
- Moundras C, Remesy C, Levrat MA, et al. Methionine deficiency in rats fed soy protein induces hypercholesterolemia and potentiates lipoprotein susceptibility to peroxidation. *Metabolism* 1995;44(9):1146-1152.
- Muller-Fassbender H. Double-blind clinical trial of S-adenosylmethionine versus ibuprofen in the treatment of osteoarthritis. *Am J Med* 1987;83(5A):81-83.
- Muller F, Svardal AM, Aukrust P, et al. Elevated plasma concentration of reduced homocysteine in patients with human immunodeficiency virus infection. *Am J Clin Nutr* 1996;63(2):242-248.
- Niculescu MD, Zeisel SH. Diet, methyl donors and DNA methylation: interactions between dietary folate, methionine and choline. *J Nutr* 2002;132(8 Suppl):233S-235S.
- Nutt JG, Woodward WR, Hammerstad JP, et al. The "on-off" phenomenon in Parkinson's disease: relation to levodopa absorption and transport. *N Engl J Med* 1984;310(8):483-488.
- O'Suilleabhain P, Diaz-Arrastia R. Levodopa elevates homocysteine: is this a problem? *Arch Neurol* 2004;61(5):633-634. (Editorial, Comment)
- Revillard JP, Vincent CM, Favier AE, et al. Lipid peroxidation in human immunodeficiency virus infection. *J Acquir Immune Defic Syndr* 1992;5(6):637-638.
- Rosenbaum JF, Fava M, Falk WE, et al. An open-label pilot study of oral S-adenosyl-L-methionine in major depression: interim results. *Psychopharmacol Bull* 1988;24(1):189-194.
- Rudiger H. [Regulatory aspects in methionine biosynthesis.] *Hoppe Seylers Z Physiol Chem* 1972;353(5):750. [German]
- Salmaggi P, Bressa GM, Nicchia G, et al. Double-blind, placebo-controlled study of S-adenosyl-L-methionine in depressed postmenopausal women. *Psychother Psychosom* 1993;59(1):34-40.
- Shapiro SK, Ehninger DJ. Enzyme regulation in the pathway of methionine biosynthesis: molecular conversion of adenosylhomocysteine to adenosylmethionine: ANL-7409. *ANL Rep* 1967:61-63.
- Shaw GM, Velie EM, Schaffer DM. Is dietary intake of methionine associated with a reduction in risk for neural tube defect-associated pregnancies? *Teratology* 1997;56:295-299.
- Singer P, Katz DP, Dillon L, et al. Nutritional aspects of the acquired immunodeficiency syndrome. *Am J Gastroenterol* 1992;87(3):265-273. (Review)
- Smythies JR, Halsey JH. Treatment of Parkinson's disease with L-methionine. *South Med J* 1984;77(12):1577.
- Song YS, Rosenfeld ME. Methionine-induced hyperhomocysteinemia promotes superoxide anion generation and NF kappa B activation in peritoneal macrophages of C57BL/6 mice. *J Med Food* 2004;7(2):229-234.
- Tan SV, Guilloff RJ. Hypothesis on the pathogenesis of vacuolar myelopathy, dementia, and peripheral neuropathy in AIDS. *J Neurol Neurosurg Psychiatry* 1998;65:23-28.
- Toborek M, Barger SW, Mattson MP, et al. Role of glutathione redox cycle in TNF-alpha-mediated endothelial cell dysfunction. *Atherosclerosis* 1995;117(2):179-188.
- Toborek M, Kopiecza-Grzebieniak E, Drozdz M, et al. Increased lipid peroxidation and antioxidant activity in methionine-induced hepatitis in rabbits. *Nutrition* 1996;12(7-8):534-537.
- Troen AM, Lutgens E, Smith DE, et al. The atherogenic effect of excess methionine intake. *Proc Natl Acad Sci U S A* 2003;100(25):15089-15094.
- Trolin CG, Lofberg C, Trolin G, et al. Brain ATP: L-methionine S-adenosyltransferase (MAT), S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH): regional distribution and age-related changes. *Eur Neuropsychopharmacol* 1994;4(4):469-477.

Citations and Reference Literature: Methionine

- USDA: Composition of foods: USDA handbook #8. Washington, DC: ARS, USDA; 1976-1986.
- Wang ST, Chen HW, Sheen LY, et al. Methionine and cysteine affect glutathione level, glutathione-related enzyme activities and the expression of glutathione S-transferase isozymes in rat hepatocytes. *J Nutr* 1997;127(11):2135-2141.
- Yamaguchi T, Nagatsu T. Effects of tyrosine administration on serum biotin in normal controls and patients with Parkinson's disease. *Science* 1983;219:75-77.
- Zhao WQ, Latinwo L, Liu XX, et al. L-dopa upregulates the expression and activities of methionine adenosyl transferase and catechol-O-methyltransferase. *Exp Neurol* 2001;171(1):127-138.